Abeona Therapeutics Inc.
- Jurisdiction
United States - LEI
54930002Z8PIJRCB4576 - ISIN
US00289Y2063 (ABEO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Read full profile
Fundamentals
- Net revenue
€341.18K - Gross margin
-119.0% - EBIT
-€63.58M - EBIT margin
-18,634.0% - Net income
€48.82M - Net margin
14,310.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.59 - Ex date
-
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
|
|
|
|
| Crombez Eric | N/A |
|
|
|
|
| Vazzano Joseph Walter | Chief Financial Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: November 16, 2023 (Q3 2023)